A subsequent study revealed that there was a high frequency mutation of KLHL14 in ABC-DLBCL, which promoted assemblage of the MYD88-TLR9-BCR complex, eventually induced resistance to ibrutinib (104). The gene discussed is MYD88; the disease is diffuse large B-cell lymphoma.